This specialist Guidelines summary covers which patient specific characteristics to consider when choosing an SGLT-2 inhibitor for a patient with type 2 diabetes and cardiovascular disease.
This summary is intended for use by secondary care cardiologists and diabetologists.
- There are no clinical trials directly comparing SGLT-2 inhibitors and the recommendations below are based on indirect comparisons
- The choice of agent and dose should always be specific to each individual patient based on their medical history and circumstances
- The guidance can be considered in consultation with the patient, guardian, or carer, and should be informed by the summaries of product characteristics (SPCs) for the relevant drug, to determine which drug options may be most appropriate for individual patients presenting with the characteristics listed
- The following algorithm is part of the 'All Wales Advice on SGLT-2 inhibitors in Type 2 Diabetes and Cardiovascular disease'. Please refer to the full guideline for supporting references, prescribing recommendations, and a comprehensive review of the evidence for SGLT-2 inhibitor use in patients with type 2 diabetes mellitus and cardiovascular disease.